Dj%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520citral

# Djcitral ## Overview Djcitral is a combination medication containing dihydroartemisinin and piperaquine phosphate, an antimalarial regimen. Dihydroartemisinin is a fast-acting derivative of artemisinin, while piperaquine phosphate has a longer half-life. ## Primary Indications Treatment of uncomplicated *Plasmodium falciparum* malaria. It is typically used as a first-line or second-line treatment depending on local resistance patterns. ## Adult Dosing The standard adult dose is 4 tablets (containing 20 mg dihydroartemisinin and 120 mg piperaquine phosphate per tablet) once daily for 3 days. This provides a total dose of 240 mg dihydroartemisinin and 1440 mg piperaquine phosphate over the treatment course. Administer with food to improve absorption. ## Pediatric Dosing Dosing is weight-based. A common regimen is 4 mg/kg of dihydroartemisinin and 20 mg/kg of piperaquine phosphate given once daily for 3 days. * **< 5 kg:** Dosing may require specialized pediatric formulations or careful weight-based calculation and administration. Local guidelines should be consulted. * **5 - < 15 kg:** 1 tablet daily for 3 days. * **15 - < 25 kg:** 2 tablets daily for 3 days. * **25 - < 35 kg:** 3 tablets daily for 3 days. * **≥ 35 kg:** 4 tablets daily for 3 days. ## Dose Adjustments No dose adjustment is typically required for hepatic or renal impairment, but caution is advised in severe impairment. ## Contraindications * Known hypersensitivity to dihydroartemisinin, piperaquine, or any excipients. * Severe hepatic or renal impairment. * Concomitant use with drugs that prolong the QT interval. ## Adverse Effects Common adverse effects include headache, dizziness, nausea, vomiting, abdominal pain, diarrhea, fatigue, and cough. Less common but serious adverse effects can include: * **Cardiovascular:** QT interval prolongation, arrhythmias. * **Hematologic:** Anemia, neutropenia. * **Hepatic:** Elevated liver enzymes. * **Neurologic:** Seizures (rare). ## Key Drug Interactions * **QTc-prolonging agents:** Increased risk of ventricular arrhythmias. Examples include certain antiarrhythmics (e.g., amiodarone, quinidine), antipsychotics, and macrolide antibiotics. * **CYP3A4 inhibitors/inducers:** May alter the metabolism of piperaquine, although clinical significance is not fully established. ## Monitoring * **ECG:** Baseline ECG and follow-up may be considered, especially in patients with risk factors for QT prolongation or those taking other QTc-prolonging medications. * **Liver function tests:** Monitor in patients with pre-existing liver disease. * **Complete blood count:** Consider monitoring in patients with known hematologic abnormalities. * Therapeutic response: Clinical and parasitological cure should be assessed. ## Clinical Pearls * Administer the full 3-day course even if symptoms improve earlier. * Take with food to maximize absorption of piperaquine. * Caution is advised in patients with cardiac conduction abnormalities or those taking other medications known to affect cardiac rhythm. * Pregnancy: Generally avoided in the first trimester due to potential risks associated with artemisinin derivatives. Consult specific guidelines. Use in the second and third trimesters may be considered if benefits outweigh risks. Lactation: Safety is not established; consult specific guidelines. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and local guidelines for complete details and to verify accuracy before making any clinical decisions.